Physician profile
John A Samsa
NPI 1932168242
$2,218.11
in general payments reported to CMS, 2019-2025
14 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,331 · 2020: $256 · 2021: $65.37 · 2022: $58.19 · 2023: $87.04 · 2024: $64.01 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,277.50 | 2019-2025 | General - Therapies, Watchman Flx |
| Abbott Laboratories | $228.18 | 2019-2020 | |
| Abiomed | $172.29 | 2019-2024 | Impella |
| Medtronic Vascular, INC. | $126.12 | 2019 | |
| Edwards Lifesciences Corporation | $123.14 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $83.55 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $53.45 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $48.38 | 2020-2025 | Brilinta |
| Medtronic, INC. | $30.56 | 2021-2023 | Onyx Frontier |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.93 | 2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $15.60 | 2025 | Camzyos |
| Amgen INC. | $14.55 | 2020 | |
| Cardinal Health 200 LLC | $13.56 | 2021 | |
| Novo Nordisk INC | $13.30 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Samsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.